{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T04:12:56Z","timestamp":1649131976892},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University Grants Commission (UGC), New Delhi, India"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Environmental Toxicology and Pharmacology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.etap.2012.07.001","type":"journal-article","created":{"date-parts":[[2012,7,14]],"date-time":"2012-07-14T09:04:11Z","timestamp":1342256651000},"page":"588-607","source":"Crossref","is-referenced-by-count":2,"title":["Correlation among the toxicity profiling (28-days repeated oral dose toxicity), toxicokinetics and tissue distribution data of ulifloxacin, the active metabolite of prulifloxacin in Wistar albino rats"],"prefix":"10.1016","volume":"34","author":[{"given":"Utpal","family":"Nandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bikash","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjan Kumar","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapan Kumar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.etap.2012.07.001_bib0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2131\/jts.29.63","article-title":"Comparative assessment of prulifloxacin, sparfloxacin, gatfloxacin, and livofloxacin in the rabbit model of proarrhythmia","volume":"29","author":"Akita","year":"2004","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.etap.2012.07.001_bib0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1742-7843.2006.pto_326.x","article-title":"Ultrastructural changes of the gemifloxacin on Achilles tendon in immature rats: comparison with those of ciproxacin and ofloxacin","volume":"98","author":"Bae","year":"2006","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.etap.2012.07.001_bib0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/dkg209","article-title":"Adverse drug reactions: implications for the development of fluoroquinolones","volume":"51","author":"Ball","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.etap.2012.07.001_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pupt.2005.09.008","article-title":"Highlights on the appropriate use of fluoroquinolones in respiratory tract infections","volume":"19","author":"Blasi","year":"2006","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.etap.2012.07.001_bib0025","doi-asserted-by":"crossref","first-page":"756","DOI":"10.7326\/0003-4819-131-10-199911160-00007","article-title":"Synovial fluid analysis for diagnosis of intercritical gout","volume":"131","author":"Eliseo","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.etap.2012.07.001_bib0030","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2165\/00003088-200544120-00007","article-title":"Penetration of orally administered prulifloxacin into human lung tissue","volume":"44","author":"Ercole","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.etap.2012.07.001_bib0035","unstructured":"Food and Drug Administration, Rockville, Maryland, 2002. Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers, USA. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research."},{"key":"10.1016\/j.etap.2012.07.001_bib0040","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1073\/pnas.74.11.4772","article-title":"Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity","volume":"74","author":"Gellert","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.etap.2012.07.001_bib0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/17460913.4.1.13","article-title":"Prulifloxacin: clinical studies of a broad-spectrum quinolone agent","volume":"4","author":"Giannarini","year":"2009","journal-title":"Future Microbiol."},{"key":"10.1016\/j.etap.2012.07.001_bib0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000063623","article-title":"Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis","volume":"69","author":"Grassia","year":"2002","journal-title":"Respiration"},{"key":"10.1016\/j.etap.2012.07.001_bib0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/14787210.4.1.27","article-title":"Prulifloxacin: a new antibacterial fluoroquinolone","volume":"4","author":"Guillem","year":"2006","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.etap.2012.07.001_bib0060","first-page":"485","article-title":"Subchronic toxicity of the new quinolone antibacterial agent irloxacin in Beagle dogs","volume":"50","author":"Guzman","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.etap.2012.07.001_bib0065","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.29.6.1073","article-title":"Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase a primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts","volume":"29","author":"Hussy","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.etap.2012.07.001_bib0070","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2131\/jts.21.SupplementI_259","article-title":"A photoallergenicity study of prulifloxacin (NM441) in guinea pigs","volume":"21","author":"Kamata","year":"1996","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.etap.2012.07.001_bib0075","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2165\/00003495-200464190-00005","article-title":"Prulifloxacin","volume":"64","author":"Keam","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.etap.2012.07.001_bib0080","doi-asserted-by":"crossref","first-page":"11801","DOI":"10.1073\/pnas.92.25.11801","article-title":"Topoisomerase IV is a target of quinolones in Escherichia coli","volume":"92","author":"Khodursky","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.etap.2012.07.001_bib0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0014-2999(03)02180-0","article-title":"Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk","volume":"477","author":"Lacroix","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.etap.2012.07.001_bib0090","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1128\/AAC.37.10.2217","article-title":"Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light","volume":"37","author":"Marutani","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.etap.2012.07.001_bib0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pupt.2005.09.009","article-title":"Pharmacologic characteristics of prulifloxacin","volume":"19","author":"Matera","year":"2006","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.etap.2012.07.001_bib0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2131\/jts.21.SupplementI_45","article-title":"4-Week oral toxicity study of prulifloxacin (NM441) in rats followed by a 4-week recovery test","volume":"21","author":"Nishimura","year":"1996","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.etap.2012.07.001_bib0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2131\/jts.21.SupplementI_71","article-title":"A 4-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 4-week recovery test","volume":"21","author":"Oda","year":"1996","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.etap.2012.07.001_bib0110","unstructured":"OECD (Organization for Economic Co-operation and Development), 1995. Guideline for the Testing of Chemicals. Guideline 407: Repeated Dose 28-Day Oral Toxicity Study in Rodents (Adopted 27.07.1995)."},{"key":"10.1016\/j.etap.2012.07.001_bib0115","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/jama.1968.03140070064014","article-title":"Compensated polarized light microscopy. Identification of crystals in synovial fluids from gout and pseudogout","volume":"203","author":"Phelps","year":"1968","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.etap.2012.07.001_bib0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/14787210.4.1.27","article-title":"Prulifloxacin: a new antibacterial fluoroquinolone","volume":"4","author":"Prats","year":"2006","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.etap.2012.07.001_bib0125","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/bmc.1539","article-title":"Development and validation of a liquid chromatography\u2013tandem mass spectrometry method to determine ulifloxacin, the active metabolite of prulifloxacin in rat and rabbit plasma: application to toxicokinetic study","volume":"25","author":"Roy","year":"2010","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.etap.2012.07.001_bib0130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.yrtph.2010.05.008","article-title":"Twenty-eight days repeated oral dose toxicity study of gemifloxacin in Wistar albino rats","volume":"58","author":"Roy","year":"2010","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.etap.2012.07.001_bib0135","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.etap.2012.07.001_bib0140","first-page":"133","article-title":"Adverse effects of fluoroquinolones","volume":"38","author":"Shimada","year":"1992","journal-title":"Prog. Drug Res."},{"key":"10.1016\/j.etap.2012.07.001_bib0145","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1128\/AAC.01260-08","article-title":"Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea","volume":"53","author":"Thomas","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.etap.2012.07.001_bib0150","first-page":"355","article-title":"Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent","volume":"26","author":"Tougou","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.etap.2012.07.001_bib0155","unstructured":"US Food and Drug Administration, 1978. Good Laboratory Practice Regulations (Part 58 of 21 Code of Federal Regulations (CFR)). Federal Register 22 December 1979 and Subsequent amendments."},{"key":"10.1016\/j.etap.2012.07.001_bib0160","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jac\/43.suppl_2.91","article-title":"Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone","volume":"43","author":"Von Keutz","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.etap.2012.07.001_bib0165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0378-4274(91)90176-7","article-title":"Quinolone antibacterial-agent-induced cutaneous phototoxicity: ear swelling reactions in Balb\/c mice","volume":"58","author":"Wagai","year":"1991","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.etap.2012.07.001_bib0170","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0378-4274(90)90197-T","article-title":"Phototoxic potential of quinolone antibacterial agents in Balb\/c mice","volume":"54","author":"Wagai","year":"1990","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.etap.2012.07.001_bib0175","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2116\/analsci.23.1373","article-title":"Determination of ulifloxacin by terbium-sensitized fluorescence with second-order scattering and its applications","volume":"23","author":"Wang","year":"2007","journal-title":"Anal. Sci."},{"key":"10.1016\/j.etap.2012.07.001_bib0180","series-title":"Animal Clinical Chemistry","first-page":"71","article-title":"Assessment of hepatotoxicity","author":"Woodman","year":"1996"},{"key":"10.1016\/j.etap.2012.07.001_bib0185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2131\/jts.21.SupplementI_113","article-title":"A 13-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 5-week recovery test","volume":"21","author":"Yoshida","year":"1996","journal-title":"Toxicol. Sci."}],"container-title":["Environmental Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1382668912001032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1382668912001032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T04:52:48Z","timestamp":1542862368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1382668912001032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1382668912001032"],"URL":"https:\/\/doi.org\/10.1016\/j.etap.2012.07.001","relation":{},"ISSN":["1382-6689"],"issn-type":[{"value":"1382-6689","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}